Distinct H3F3A and H3F3B driver mutations define chondroblastoma and giant cell tumor of bone
暂无分享,去创建一个
M. Stratton | P. Futreal | P. Campbell | J. Teague | O. Myklebost | P. Tarpey | P. Loo | D. Wedge | S. Nik-Zainal | Sancha Martin | A. Butler | S. McLaren | G. Gundem | P. Van Loo | H. Davies | S. Behjati | S. Cooke | A. Flanagan | R. Hamoudi | D. Baumhoer | V. Goody | N. Pillay | R. Tirabosco | S. Scheipl | B. Robinson | N. Presneau | D. Halai | G. Jundt | B. Khatri | M. Amary | Victoria Goodie | Stuart McLaren | Stuart Mclaren
[1] Dongfang Li,et al. Genome sequencing of 161 Mycobacterium tuberculosis isolates from China identifies genes and intergenic regions associated with drug resistance , 2013, Nature Genetics.
[2] David Beare,et al. Frequent mutation of the major cartilage collagen gene COL2A1 in chondrosarcoma , 2013, Nature Genetics.
[3] B. Garcia,et al. Inhibition of PRC2 Activity by a Gain-of-Function H3 Mutation Found in Pediatric Glioblastoma , 2013, Science.
[4] Sabine Mueller,et al. The histone H3.3K27M mutation in pediatric glioma reprograms H3K27 methylation and gene expression. , 2013, Genes & development.
[5] A. Ashworth,et al. Histone H3.3. mutations drive pediatric glioblastoma through upregulation of MYCN. , 2013, Cancer discovery.
[6] Heather L. Mulder,et al. Whole-genome sequencing identifies genetic alterations in pediatric low-grade gliomas , 2013, Nature Genetics.
[7] C. Kramm,et al. H3F3A K27M mutation in pediatric CNS tumors: a marker for diffuse high-grade astrocytomas. , 2013, American journal of clinical pathology.
[8] T. Pietsch,et al. H3.3 G34R mutations in pediatric primitive neuroectodermal tumors of central nervous system (CNS-PNET) and pediatric glioblastomas: possible diagnostic and therapeutic implications? , 2013, Journal of Neuro-Oncology.
[9] David T. W. Jones,et al. K27M mutation in histone H3.3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomas , 2012, Acta Neuropathologica.
[10] A. Børresen-Dale,et al. Mutational Processes Molding the Genomes of 21 Breast Cancers , 2012, Cell.
[11] A. Børresen-Dale,et al. The landscape of cancer genes and mutational processes in breast cancer , 2012, Nature.
[12] H. Knowles,et al. CD14− mononuclear stromal cells support (CD14+) monocyte–osteoclast differentiation in aneurysmal bone cyst , 2012, Laboratory Investigation.
[13] David T. W. Jones,et al. Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma , 2012, Nature.
[14] Li Ding,et al. Somatic Histone H3 Alterations in Paediatric Diffuse Intrinsic Pontine Gliomas and Non-Brainstem Glioblastomas , 2012, Nature Genetics.
[15] A. Fernández-Medarde,et al. Ras in cancer and developmental diseases. , 2011, Genes & cancer.
[16] G. Almouzni,et al. The double face of the histone variant H3.3 , 2011, Cell Research.
[17] C. Perou,et al. Allele-specific copy number analysis of tumors , 2010, Proceedings of the National Academy of Sciences.
[18] Richard Durbin,et al. Fast and accurate long-read alignment with Burrows–Wheeler transform , 2010, Bioinform..
[19] Kai Ye,et al. Pindel: a pattern growth approach to detect break points of large deletions and medium sized insertions from paired-end short reads , 2009, Bioinform..
[20] M. Stratton,et al. The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website , 2004, British Journal of Cancer.
[21] W. Albig,et al. Differential expression of human replacement and cell cycle dependent H3 histone genes. , 2003, Gene.
[22] G. Delling,et al. The nature of giant cell tumor of bone , 2001, Journal of Cancer Research and Clinical Oncology.
[23] J. Del Mazo,et al. Developmental expression of H3.3A variant histone mRNA in mouse. , 1997, The International journal of developmental biology.
[24] E. Silbergeld,et al. P53 mutations associated with breast, colorectal, liver, lung, and ovarian cancers. , 1996, Environmental health perspectives.
[25] B. Bramlage,et al. The human replacement histone H3.3B gene (H3F3B). , 1995, Genomics.
[26] M. Horton,et al. Arg-Gly-Asp (RGD) peptides and the anti-vitronectin receptor antibody 23C6 inhibit dentine resorption and cell spreading by osteoclasts. , 1991, Experimental cell research.
[27] M. Horton,et al. Monoclonal antibodies to osteoclastomas (giant cell bone tumors): definition of osteoclast-specific cellular antigens. , 1985, Cancer research.
[28] P. Komminoth,et al. Pathology and Genetics of Tumours of Soft Tissue and Bone , 2013 .
[29] Claude-Alain H. Roten,et al. Fast and accurate short read alignment with Burrows–Wheeler transform , 2009, Bioinform..